RT Journal Article
SR Electronic
T1 An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with <sup>18</sup>F-PM-PBB3 (<sup>18</sup>F-APN-1607)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.13.22270135
DO 10.1101/2022.02.13.22270135
A1 Kenji Tagai
A1 Yoko Ikoma
A1 Hironobu Endo
A1 Oiendrila Bhowmik Debnath
A1 Chie Seki
A1 Kiwamu Matsuoka
A1 Hideki Matsumoto
A1 Masaki Oya
A1 Kosei Hirata
A1 Hitoshi Shinotoh
A1 Keisuke Takahata
A1 Shin Kurose
A1 Yasunori Sano
A1 Maiko Ono
A1 Hitoshi Shimada
A1 Kazunori Kawamura
A1 Ming-Rong Zhang
A1 Yuhei Takado
A1 Makoto Higuchi
YR 2022
UL http://medrxiv.org/content/early/2022/02/17/2022.02.13.22270135.abstract
AB Positron emission tomography (PET) with 18F-PM-PBB3 (18F-APN-1607) enables high-contrast detection of tau depositions in various neurodegenerative dementias, including Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD). A simplified method for quantifying the radioligand binding in target regions is to employ the cerebellum as a reference (CB-ref) on the assumption that the cerebellum has minimal tau pathologies. This procedure could be valid in AD, while FTLD disorders exemplified by progressive supranuclear palsy (PSP) are characterized by occasional tau accumulations in the cerebellum, hampering the application of CB-ref. The present study aimed to establish an optimal method for defining reference tissues on 18F-PM-PBB3-PET images of the AD and non-AD tauopathy brains. We developed a new algorithm to extract reference voxels with a low likelihood of containing tau deposits from gray matter (GM-ref) or white matter (WM-ref) by a bimodal fit to an individual, voxel-wise histogram of the radioligand retentions and applied it to 18F-PM-PBB3-PET data obtained from age-matched 40 healthy controls (HCs) and 23 AD, 40 PSP, and five other tau-positive FTLD patients. PET images acquired at 90-110 min after injection were averaged and co-registered to corresponding magnetic resonance imaging space. Subsequently, we generated standardized uptake value ratio (SUVR) images estimated by CB-ref, GM-ref and WM-ref respectively, and then compared the diagnostic performances. GM-ref and WM-ref covered a broad area in HCs and free of voxels located in regions known to bear high tau burdens in AD and PSP patients. GM-ref allowed the most robust separation of AD and PSP patients from HCs according to the area under the curves in receiver operating characteristic curve analyses. GM-ref also provided SUVR images with higher contrast than CB-ref in FTLD patients with suspected and confirmed corticobasal degeneration. The methodology for determining reference tissues as optimized here reinforces the accuracy of 18F-PM-PBB3-PET measurements of tau burdens in a wide range of neurodegenerative illnesses.Competing Interest StatementHitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).Clinical TrialUMIN-CTR; IDs 000030248, 000034546, 000033808, and 000030319Funding StatementThis study was supported in part by AMED under Grant Number JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049, and by MEXT KAKENHI Grant Number JP16H05324, JP18K07543, by JST CREST Grant Number JPMJCR1652 and by Biogen Idec Inc. and APRINOIA Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Radiation Drug Safety Committee and National Institutes for Quantum Science and Technology Certified Review Board of Japan gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data that support the findings of this study should be directed to Correspondence, Kenji Tagai (tagai.kenji{at}qst.go.jp) and Yuhei Takado (takado.yuhei{at}qst.go.jp), and will be available upon reasonable request.